BioLine RX Ltd (BLRX) FinancialsBLRXBioLine RX Ltd

Evaluating the bottom line, BioLine RX Ltd maintains a gross margin of 79.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1745.36%, while the net margin is -1152.58%. These profitability ratios, combined with a Return on Equity (ROE) of -12.80%, provide a clear picture of how effectively BLRX converts its operational activities into shareholder value.

In the context of the broader market, BLRX competes directly with industry leaders such as CPHI and ACTU. With a market capitalization of $12.01M, it holds a significant position in the sector. When comparing efficiency, BLRX's gross margin of 79.38% stands against CPHI's 8.81% and ACTU's N/A. Such benchmarking helps identify whether BioLine RX Ltd is trading at a premium or discount relative to its financial performance.

BioLine RX has shown mixed financial performance, with a gross margin of 79.38% in the last quarter, but a net income of -$2.24 million. Revenue in Q1 2026 was $0.48 million, an 84.6% increase year-over-year, but the overall trend shows volatility and losses in other quarters.